Gyre Therapeutics Stock Price on November 12, 2024
| GYRE Stock | 11.75 1.16 8.99% |
Below is the normalized historical share price chart for Gyre Therapeutics extending back to April 12, 2006. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Gyre Therapeutics stands at 11.75, as last reported on the 22nd of November, with the highest price reaching 12.91 and the lowest price hitting 11.70 during the day.
If you're considering investing in Gyre Stock, it is important to understand the factors that can impact its price. Gyre Therapeutics holds Efficiency (Sharpe) Ratio of -0.0425, which attests that the entity had a -0.0425% return per unit of risk over the last 3 months. Gyre Therapeutics exposes twenty-nine different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Gyre Therapeutics' Market Risk Adjusted Performance of 0.0437, risk adjusted performance of 0.0215, and Downside Deviation of 4.71 to validate the risk estimate we provide.
At present, Gyre Therapeutics' Liabilities And Stockholders Equity is projected to decrease significantly based on the last few years of reporting. The current year's Common Stock is expected to grow to about 80.8 K, whereas Other Stockholder Equity is forecasted to decline to about 3.5 M. . At present, Gyre Therapeutics' Price To Free Cash Flows Ratio is projected to increase significantly based on the last few years of reporting. The current year's Price Cash Flow Ratio is expected to grow to 63.51, whereas Price Earnings Ratio is projected to grow to (16.01). Gyre Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 12th of April 2006 | 200 Day MA 14.1622 | 50 Day MA 13.7634 |
Gyre |
Sharpe Ratio = -0.0425
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | GYRE |
Estimated Market Risk
| 4.31 actual daily | 38 62% of assets are more volatile |
Expected Return
| -0.18 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Gyre Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Gyre Therapeutics by adding Gyre Therapeutics to a well-diversified portfolio.
Price Book 15.9612 | Enterprise Value Ebitda 83.4701 | Price Sales 9.037 | Shares Float 15.8 M | Earnings Share (1.04) |
Related Headline
Alaska Air Headline on 12th of November 2024
Boeings most immediate problem an eight-week strike by 33,000 workers is over. But its more serious problems ongoing massive losses, quality and safety problems are as bad as ever, and could even get worse.
Gyre Therapeutics Valuation on November 12, 2024
It is possible to determine the worth of Gyre Therapeutics on a given historical date. On November 12, 2024 Gyre was worth 16.71 at the beginning of the trading date compared to the closed value of 16.01. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Gyre Therapeutics stock. Still, in general, we apply an absolute valuation method to find Gyre Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Gyre Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Gyre Therapeutics' related companies.
| Open | High | Low | Close | Volume | |
| 15.39 | 16.82 | 15.01 | 16.80 | 117,488 | |
11/12/2024 | 16.71 | 19.00 | 15.55 | 16.01 | 164,512 |
| 15.55 | 16.06 | 13.07 | 14.48 | 165,953 |
| Backtest Gyre Therapeutics | | | Gyre Therapeutics History | | | Gyre Therapeutics Valuation | Previous | Next |
Gyre Therapeutics Trading Date Momentum on November 12, 2024
| On November 13 2024 Gyre Therapeutics was traded for 14.48 at the closing time. The top price for the day was 16.06 and the lowest listed price was 13.07 . The trading volume for the day was 166 K. The trading history from November 13, 2024 was a factor to the next trading day price decrease. The overall trading delta against the next closing price was 9.56% . The overall trading delta against the current closing price is 19.61% . |
Gyre Therapeutics Fundamentals Correlations and Trends
By evaluating Gyre Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Gyre Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Gyre financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Gyre Therapeutics Stock history
Gyre Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Gyre is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Gyre Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Gyre Therapeutics stock prices may prove useful in developing a viable investing in Gyre Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 65.8 M | 69.1 M |
Gyre Therapeutics Quarterly Net Working Capital |
|
Gyre Therapeutics Stock Technical Analysis
Gyre Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Gyre Therapeutics Period Price Range
Low | November 22, 2024
| High |
0.00 | 0.00 |
Gyre Therapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Gyre Therapeutics November 22, 2024 Market Strength
Market strength indicators help investors to evaluate how Gyre Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Gyre Therapeutics shares will generate the highest return on investment. By undertsting and applying Gyre Therapeutics stock market strength indicators, traders can identify Gyre Therapeutics entry and exit signals to maximize returns
Gyre Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Gyre Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Gyre Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Gyre to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.0215 | |||
| Jensen Alpha | (0.14) | |||
| Total Risk Alpha | (0.54) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | 0.0337 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Complementary Tools for Gyre Stock analysis
When running Gyre Therapeutics' price analysis, check to measure Gyre Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gyre Therapeutics is operating at the current time. Most of Gyre Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gyre Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gyre Therapeutics' price. Additionally, you may evaluate how the addition of Gyre Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |